Skip to main content
Explore URMC

Daniel L. Mulkerin, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Professional Background

Dr. Mulkerin's clinical practice is focused on gastrointestinal malignancies. He is actively involved in clinical research. He is a highly respected mentor and has extensive teaching experience. Dr. Mulkerin holds an important role in enhancing and advancing the Department of Medicine's footprint in our region.



MD | Thomas Jefferson University Hospital (USA)

Post-doctoral Training & Residency

07/01/1996 - 06/30/1999
Fellowship in Medical Oncology at University of Wisconsin Hospital and Clinics

06/25/1993 - 06/30/1996
Residency in Internal Medicine at University of Wisconsin Hospital and Clinics

06/24/1992 - 06/24/1993
Internship in Internal Medicine at University of Wisconsin Hospital and Clinics

VIEW ALL expand_more


2017 - 2018
Award for Service/Leadership Excellence

UW Health Patient Experience Physician Champion Award

UW Health Physician Excellence Regional Services Award

UW Health Patient Experience Physician Champion Award

2013 - 2021
Top Doctor's in America

Top Doctors: Madison Magazine

Hobart Armory Hare Honor Society
Location: Jefferson Medical College

UW Hematology/Oncology Division/Department of Medicine

VIEW ALL expand_more

Clinical Trials

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Lead Researcher: Daniel L Mulkerin

The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.

View Study Details

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Lead Researcher: Daniel L Mulkerin

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

View Study Details